Left Brain Wealth Management’s AbbVie ABBV Stock Holding History

Left Brain Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,699	Closed	-$587K	–	100
2026 Q1	$587K	Sell	2,699 -40	-1%	-$8.87K	0.23%	52
2025 Q4	$626K	Hold	2,739	–	–	0.22%	53
2025 Q3	$634K	Sell	2,739 -1,006	-27%	-$205K	0.2%	61
2025 Q2	$695K	Sell	3,745 -225	-6%	-$41.8K	0.24%	54
2025 Q1	$832K	Sell	3,970 -325	-8%	-$63.2K	0.36%	46
2024 Q4	$763K	Sell	4,295 -425	-9%	-$78.1K	0.29%	51
2024 Q3	$932K	Sell	4,720 -694	-13%	-$130K	0.43%	45
2024 Q2	$929K	Sell	5,414 -40	-0.7%	-$6.63K	0.43%	41
2024 Q1	$993K	Sell	5,454 -412	-7%	-$71K	0.48%	41
2023 Q4	$909K	Sell	5,866 -132	-2%	-$19.2K	0.53%	45
2023 Q3	$894K	Sell	5,998 -1	-0%	-$147	0.56%	43
2023 Q2	$808K	Sell	5,999 -492	-8%	-$72.1K	0.49%	51
2023 Q1	$981K	Sell	6,491 -8,703	-57%	-$1.33M	0.67%	44
2022 Q4	$2.46M	Buy	+15,194	New	+$2.33M	1.84%	22

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Left Brain Wealth Management's ABBV Position: Q2 2026 in Review

Left Brain Wealth Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 2,699 shares — an estimated $587K sold.

Left Brain Wealth Management first reported a position in ABBV in Q4 2022 and held it in 14 quarters. The position peaked at $2.46M in Q4 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Left Brain Wealth Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Left Brain Wealth Management sold 2,699 AbbVie shares in Q2 2026, an estimated $587K.
Left Brain Wealth Management first reported a position in AbbVie in Q4 2022 and held it in 14 quarters.
Left Brain Wealth Management's AbbVie position peaked at $2.46M in Q4 2022.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Left Brain Wealth Management's 13F filing for Q2 2026, filed 30 Jul 2026.